KFS
REGN icon

Keynote Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Keynote Financial Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$879K Buy
1,138
+2
+0.2% +$1.53K 0.47% 61
2025
Q4 		$877K Buy
1,136
+43
+4% +$29.2K 0.49% 58
2025
Q3 		$615K Buy
1,093
+221
+25% +$125K 0.37% 76
2025
Q2 		$458K Buy
872
+245
+39% +$137K 0.31% 88
2025
Q1 		$398K Buy
627
+88
+16% +$60.5K 0.28% 97
2024
Q4 		$384K Buy
539
+41
+8% +$34.4K 0.29% 97
2024
Q3 		$524K Sell
498
-18
-3% -$20K 0.4% 72
2024
Q2 		$542K Buy
516
+16
+3% +$15.5K 0.45% 62
2024
Q1 		$481K Buy
+500
New +$475K 0.4% 72

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Keynote Financial Services's REGN Position: Q1 2026 in Review

Keynote Financial Services increased its Regeneron Pharmaceuticals (REGN) stake by 0.18% in Q1 2026, buying an estimated $1.53K and bringing the position to 1,138 shares worth $879K. The position accounts for 0.47% of the portfolio, ranked #61.

Keynote Financial Services first reported a position in REGN in Q1 2024 and has held it in 9 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Keynote Financial Services held 1,138 shares of Regeneron Pharmaceuticals worth $879K as of Q1 2026.
  • Keynote Financial Services bought 2 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.53K.
  • Regeneron Pharmaceuticals made up 0.47% of Keynote Financial Services's portfolio in Q1 2026, its #61 holding.
  • Keynote Financial Services first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Keynote Financial Services's 13F filing for Q1 2026, filed 13 May 2026.